Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2026)

Alnylam Pharmaceuticals has reported Raw Materials for 9 years, with the latest figure at $11.7 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials fell 50.05% year-over-year to $11.7 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (down 50.05% YoY), and the FY2025 full-year result was $14.2 million, down 40.81% from the prior year.
• Raw Materials for Q1 2026 stood at $11.7 million, down from $14.2 million in the prior quarter.
• The five-year high for Raw Materials was $26.0 million in Q2 2024, with the low at $11.7 million in Q1 2026.
• Historically, Raw Materials has averaged $20.9 million across 5 years, with a median of $22.3 million in 2022.
• The largest YoY upside for Raw Materials was 51.25% in 2022 against a maximum downside of 72.81% in 2022.
• Alnylam Pharmaceuticals' Raw Materials stood at $22.3 million in 2022, then rose by 4.62% to $23.3 million in 2023, then increased by 2.65% to $24.0 million in 2024, then sank by 40.81% to $14.2 million in 2025, then slipped by 17.6% to $11.7 million in 2026.
• The last three Raw Materials figures came in at $11.7 million (Q1 2026), $14.2 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.